Emergent BioSolutions Inc. is conducting phase clinical 3 trials of its plasma-derived therapy for outpatient treatment of COVID-19, the company announced this week.
The randomized clinical trial will assign participants to receive infusions of either a placebo or the plasma treatment. Emergent is one of two companies providing hyperimmune globulin products for the trial, which plans to enroll 820 patients across the U.S. and abroad.
{iframe}https://www.baltimoresun.com/coronavirus/bs-md-emergent-plasma-therapy-20210829-kuxvlxcnkbexraqb2erew6vjou-story.html{/iframe}